Search
Tools content (print, share, increase/decrease text size):
-
Size
Middle area:Press releases 2008Press releases are intended to journalists, analysts and investors. DIONYSOS study results showed the respective profiles of dronedarone and amiodaroneDecember 23, 2008 Sanofi-aventis and Novozymes announce a development and commercialization collaboration for an innovative antibioticDecember 22, 2008 INTANZA® / IDflu®, first intradermal influenza vaccine recommended in the European UnionDecember 18, 2008 Board of Directors dated December 17, 2008 - Corporate GovernanceDecember 18, 2008 Sanofi-aventis was granted the 2008 China Charity Award by the Ministry of Civil Affairs of the People’s Republic of ChinaDecember 15, 2008 Sanofi-aventis and Bristol-Myers Squibb prevail before the U.S. Court of Appeals for the Federal Circuit in the U.S Plavix® patent infringement caseDecember 12, 2008 Results of a phase III trial on Elitek® presented at ASH Annual MeetingDecember 07, 2008 Chris Viehbacher takes up his position as Chief Executive OfficerDecember 01, 2008 FDA intends to have an Advisory Committee meeting for Multaq® (dronedarone) on March 18, 2009November 27, 2008 Sanofi-aventis Europe’s recommended Offer for Zentiva to remain open until February 20, 2009November 26, 2008 Sanofi-aventis announces the settlement of Nasacort® AQ U.S. patent litigation and certain Allegra®/Allegra® D-12 U.S. patent litigationsNovember 19, 2008 Russia chooses inactivated Polio vaccine from Sanofi Pasteur for primary immunization of all infantsNovember 12, 2008 Dronedarone (Multaq®) reduced the incidence and duration of hospitalization in patients with atrial fibrillationNovember 11, 2008 Sanofi Pasteur first international vaccine company to enter Japan with pediatric vaccineNovember 10, 2008 Publication in the American Heart Journal of CURRENT-OASIS 7 trial designNovember 06, 2008 Sanofi-aventis to discontinue all clinical trials with rimonabantNovember 05, 2008 New ADA/EASD treatment recommendations: timely use of basal insulin reinforced as a “Core Therapy” for type 2 diabetesOctober 30, 2008 FDA approves rapid-acting insulin Apidra® for treatment of children with diabetesOctober 29, 2008 High-dose influenza vaccine shows increased immune response among adults 65 years of age and olderOctober 26, 2008 Sanofi-aventis is complying with the EMEA’s recommendation to temporarily suspend the marketing authorisation of Acomplia® in obese and overweight patientsOctober 23, 2008 Sanofi-aventis and Medicines for Malaria Venture enter into collaboration to fight MalariaOctober 22, 2008 Sanofi-aventis expands its R&D presence in ChinaOctober 21, 2008 Coarsucam™ (artesunate/amodiaquine) first fixed-dose antimalarial combination to receive WHO PrequalificationOctober 16, 2008 Sanofi-aventis enters into collaboration with TB Alliance to fight TuberculosisOctober 14, 2008 Sanofi-aventis signs a collaboration agreement with RainDance Technologies and Louis Pasteur University to launch dScreen Consortium within “Alsace BioValley” clusterSeptember 26, 2008 Sanofi Pasteur completes the acquisition of AcambisSeptember 25, 2008 FDA approves Nasacort AQ® nasal spray for children aged 2-5 years oldSeptember 23, 2008 Sanofi-aventis strengthens its position in the Dow Jones Sustainability World IndexSeptember 22, 2008 Sanofi-aventis announces intention to raise offer for Zentiva to CZK 1150 in cash per shareSeptember 22, 2008 Sanofi-aventis europe’s offer for Zentiva NV to remain open until November 28, 2008September 18, 2008 Multi-pronged therapeutic cancer vaccine regimen to be studied in melanoma patientsSeptember 17, 2008 New study results support the “Basal Plus” strategy with LANTUS® and APIDRA® to improve blood sugar control in patients with type 2 diabetesSeptember 10, 2008 People with type 2 diabetes treated with LANTUS® and APIDRA® achieved greater reductions in A1C than those treated with pre-mixed insulinSeptember 10, 2008 Upcoming change of Chief Executive OfficerSeptember 10, 2008 New real life studies illustrate greater A1C lowering and cost benefit observed with LANTUS® over detemir and NPH insulinSeptember 08, 2008 Inauguration of the sanofi-aventis Central Anti-Counterfeit Laboratory in ToursSeptember 04, 2008 Further analysis from ATHENA study showed that Multaq® (dronedarone) reduced the risk of stroke in patients with atrial fibrillationSeptember 03, 2008 Acambis’ shareholders approve Sanofi Pasteur Holding’s offer by a large majoritySeptember 02, 2008 Sanofi-aventis acquisition of Symbion Consumer in Australia now completedSeptember 01, 2008 “Taxotere® Injection” (docetaxel hydrate) approved in Japan for the treatment of prostate cancerSeptember 01, 2008 Multaq® (dronedarone) granted FDA Priority Review for patients with atrial fibrillationAugust 08, 2008 Sanofi Pasteur shipping first doses of influenza vaccine for the 2008-2009 season in the USAugust 01, 2008 Availability on line of the Group’s half-year financial report for 2008July 31, 2008 Recommended Offer by Sanofi Pasteur for Acambis plcJuly 25, 2008 European Commission approved APIDRA® for treatment of children & adolescents with diabetesJuly 24, 2008 Newly published study results showed that two mealtime insulin dosing algorithms were effective for patients with type 2 diabetesJuly 22, 2008 Sanofi-aventis and DNDi welcome the Clinton Foundation announcement on ACTs and commit to providing fixed dose combination ASAQ at equally low pricesJuly 21, 2008 Sanofi-aventis enters into agreement with Primary Health Care to acquire “Symbion Consumer”, its nutraceuticals & OTC division, in AustraliaJuly 21, 2008 Sanofi-aventis announces the termination of development and commercialization agreement for S-1 with Taiho PharmaceuticalJuly 18, 2008 Sanofi-aventis signs a collaboration agreement with The Johns Hopkins University School of Medicine to find new therapies for respiratory & immuno-allergic diseasesJuly 17, 2008 Publication of Sanofi-aventis Europe’s Offer of CZK 1,050 in cash per share for Zentiva N.VJuly 11, 2008 Sanofi Pasteur inaugurates High Tech vaccine production facility to respond to soaring demand worldwideJune 25, 2008 U.S. FDA licenses Sanofi Pasteur’s new pediatric combination vaccine, Pentacel®June 23, 2008 Sanofi-aventis intends to make a Competing Bid of CZK 1,050 in cash per share for ZentivaJune 18, 2008 Sanofi-aventis becomes a major partner in the biotechnology field in year leading to BIO 2008June 17, 2008 Sanofi Pasteur to donate 60 million doses of H5N1 vaccine to WHO over 3 years for its influenza vaccine global stockpileJune 16, 2008 Ambien CR® improved insomnia and daily functioning in patients with co-morbid major depressive disorderJune 10, 2008 Acomplia (rimonabant) significantly improved glucose control in type 2 diabetes patients treated with insulinJune 10, 2008 Five-year safety study examines the effect of LANTUS® on the progression of retinopathy in people with type 2 diabetesJune 10, 2008 Study shows LANTUS® helped people living with type 2 diabetes reach the ADA’s recommended target for blood sugar controlJune 07, 2008 Insulin Glulisine APIDRA® efficacy in the treatment of children and adolescents with type 1 diabetesJune 07, 2008 New diabetes compound AVE0010 showed clear dose response results with once-a-day injection in phase IIb studyJune 07, 2008 Sanofi-aventis and Oxford BioMedica report encouraging Trovax® Phase II trial results in metastatic renal cancerJune 02, 2008 Statement on third-party clopidogrel applications in GermanyMay 28, 2008 New Eloxatin® (oxaliplatin injection) prescribing information in the U.S includes six-year overall survival dataMay 28, 2008 Node-negative early stage breast cancer patients benefit from Taxotere®-based chemotherapyMay 27, 2008 ATHENA Clinical Results with Dronedarone (Multaq®) Highlighted at the World Congress of CardiologyMay 21, 2008 Sanofi-aventis and Regeneron Update Aflibercept (VEGF Trap) Clinical Development Program in OncologyMay 21, 2008 Landmark ATHENA Study Findings With Multaq® (dronedarone) Show 24% Reduction in Cardiovascular Hospitalisation or Death in Patients With Atrial FibrillationMay 15, 2008 District Court Decision affirmed in U.S. Lovenox® (enoxaparin sodium) patent infringement caseMay 15, 2008 Encouraging first-quarter 2008 results - Further positive Phase III results for eplivanserinApril 30, 2008 U.S. Government accepts $192 million of Sanofi Pasteur H5N1 bulk vaccine antigen for pandemic stockpileApril 28, 2008 Malaria: strong partnerships aiming to benefit patients in AfricaApril 22, 2008 Sanofi Pasteur invests 100 million Canadian dollars in an R&D facility in Canada to Boost Innovation in Vaccine Research for Global HealthApril 15, 2008 Information available concerning the Ordinary General Meeting of May 14, 2008April 10, 2008 NICE Recommends Acomplia® to be included in the NHS GuidanceMarch 26, 2008 Perioperative Eloxatin®-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver MetastasesMarch 21, 2008 U.S. FDA Licenses DAPTACEL® Vaccine for the Fifth Consecutive Dose in the Pediatric DTaP Immunization SeriesMarch 13, 2008 Filing of the 2007 U.S. Form 20-F and French “Document de Référence” and Annual Financial ReportMarch 07, 2008 New 300mg loading dose tablet for Plavix® receives positive opinion from the European Committee for Medicinal Products (CHMP)March 05, 2008 OneWorld Health, Amyris Biotechnologies and Sanofi-aventis Announce Development Agreement for Semisynthetic ArtemisininMarch 03, 2008 Sanofi Pasteur Mounts Emergency Response to Yellow Fever Epidemic in Latin AmericaFebruary 26, 2008 FDA approves XYZAL® (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic UrticariaFebruary 19, 2008 Sanofi-aventis’ SoloSTAR® insulin pen for Lantus and Apidra receives the prestigious GOOD DESIGN AwardFebruary 14, 2008 Sanofi Pasteur and Statens Serum Institut team up against TuberculosisFebruary 14, 2008 Sanofi Pasteur files for European Approval of the first seasonal influenza vaccine delivered by intradermal microinjectionFebruary 13, 2008 2007 earnings ahead of guidance - Sharp rise in proposed dividendFebruary 12, 2008 Sanofi-aventis enters into Antibody Agreements with Dyax for the fully human monoclonal antibody DX-2240 and "Phage Display Technology"February 12, 2008 “Pathways of Solidarity” - a book and an exhibitionFebruary 07, 2008 "My child matters": 25 programmes in 16 countries to fight childhood cancersFebruary 04, 2008 Clexane®/Lovenox® approved in JapanJanuary 28, 2008 Ambien CR® (zolpidem tartrate extended-release) tablets CIV improved chronic insomnia in patients with co-morbid generalized anxiety disorderJanuary 04, 2008 Sanofi Pasteur Enters Agreement with Crucell for Next-generation Biologicals against RabiesJanuary 03, 2008 |
Tools menu:
© Sanofi 2004-2013 - All rights reserved - Update: January 28, 2013
